Mass spectrometric immunoassays for discovery, screening and quantification of clinically relevant proteoforms

References

• 1 Smith LM, Kelleher NL, Proteomics CfTD. Proteoform: a single term describing protein complexity. Nat. Methods 10(3), 186–187 (2013).
  Medline CASGoogle Scholar
• 2 Roy B, Haupt LM, Griffiths LR. Review: alternative splicing (AS) of genes as an approach for generating protein complexity. Curr. Genomics 14(3), 182–194 (2013).
  Medline CASGoogle Scholar
• 3 Wu JR, Zeng R. Molecular basis for population variation: from SNPs to SAPs. FEBS Lett. 586(18), 2841–2845 (2012).
  Medline CASGoogle Scholar
• 4 Farley AR, Link AJ. Identification and quantification of protein posttranslational modifications. Methods Enzymol. 463, 725–763 (2009).
  Medline CASGoogle Scholar
• 5 Kim H, Eliuk S, Deshane J et al. 2D gel proteomics: an approach to study age-related differences in protein abundance or isoform complexity in biological samples. Methods Mol. Biol. 371, 349–391 (2007).
  Medline CASGoogle Scholar
• 6 Corzett TH, Fodor IK, Choi MW et al. Statistical analysis of variation in the human plasma proteome. J. Biomed. Biotechnol. 258494 (2010).
  MedlineGoogle Scholar
• 7 Jackson D, Herath A, Swinton J et al. Considerations for powering a clinical proteomics study: Normal variability in the human plasma proteome. Proteomics Clin. Appl. 3(3), 394–407 (2009).
  Medline CASGoogle Scholar
• 8 Ignjatovic V, Lai C, Summerhayes R et al. Age-related differences in plasma proteins: how plasma proteins change from neonates to adults. PLoS ONE 6(2), e17213 (2011).
  Medline CASGoogle Scholar
• 9 Siuti N, Kelleher NL. Decoding protein modifications using top-down mass spectrometry. Nat. Methods 4(10), 817–821 (2007).
  Medline CASGoogle Scholar
• 10 Zhang H, Ge Y. Comprehensive analysis of protein modifications by top-down mass spectrometry. Circ. Cardiovasc. Genet. 4(6), 711 (2011).
  MedlineGoogle Scholar
• 11 Stastna M, Van Eyk JE. Analysis of protein isoforms: can we do it better? Proteomics 12(19–20), 2937–2948 (2012).
  Medline CASGoogle Scholar
• 12 Wu J, Pungaliya P, Kraynov E, Bates B. Identification and quantification of osteopontin splice variants in the plasma of lung cancer patients using immunoaffinity capture and targeted mass spectrometry. Biomarkers 17(2), 125–133 (2012).
  Medline CASGoogle Scholar
• 13 Végvári A, Sjödin K, Rezeli M et al. Identification of a novel proteoform of prostate specific antigen (SNP-L132I) in clinical samples by multiple reaction monitoring. Mol. Cell Proteomics 12(10), 2761–2773 (2013).
  Medline CASGoogle Scholar
• 14 Su ZD, Sun L, Yu DX et al. Quantitative detection of single amino acid polymorphisms by targeted proteomics. J. Mol. Cell Biol. 3(5), 309–315 (2011).
  MedlineGoogle Scholar
• 15 Tipton JD, Tran JC, Catherman AD, Ahlf DR, Durbin KR, Kelleher NL. Analysis of intact protein isoforms by mass spectrometry. J. Biol. Chem. 286(29), 25451–25458 (2011).
  Medline CASGoogle Scholar
• 16 Nelson RW, Borges CR. Mass spectrometric immunoassay revisited. J. Am. Soc. Mass Spectrom. 22(6), 960–968 (2011).
  Medline CASGoogle Scholar
• 17 Nedelkov D. Mass spectrometry-based protein assays for in vitro diagnostic testing. Expert Rev. Mol. Diagn. 12(3), 235–239 (2012).
  Medline CASGoogle Scholar
• 18 Kiernan UA, Phillips DA, Trenchevska O, Nedelkov D. Quantitative mass spectrometry evaluation of human retinol binding protein 4 and related variants. PLoS ONE 6(3), e17282 (2011).
  Medline CASGoogle Scholar
• 19 Trenchevska O, Kamcheva E, Nedelkov D. Mass spectrometric immunoassay for quantitative determination of protein biomarker isoforms. J. Proteome Res. 9(11), 5969–5973 (2010).
  Medline CASGoogle Scholar
• 20 Trenchevska O, Kamcheva E, Nedelkov D. Mass spectrometric immunoassay for quantitative determination of transthyretin and its variants. Proteomics 11(18), 3633–3641 (2011).
  Medline CASGoogle Scholar
• 21 Trenchevska O, Nedelkov D. Targeted quantitative mass spectrometric immunoassay for human protein variants. Proteome Sci. 9(1), 19 (2011).
  Medline CASGoogle Scholar
• 22 Oran PE, Trenchevska O, Nedelkov D et al. Parallel workflow for high-throughput (>1,000 samples/day) quantitative analysis of human insulin-like growth factor 1 using mass spectrometric immunoassay. PLoS ONE 9(3), e92801 (2014).
  MedlineGoogle Scholar
• 23 Sherma ND, Borges CR, Trenchevska O et al. Mass spectrometric immunoassay for the qualitative and quantitative analysis of the cytokine macrophage migration inhibitory factor (MIF). Proteome Sci. 12(1), 52 (2014).
  MedlineGoogle Scholar
• 24 Trenchevska O, Schaab MR, Nelson RW, Nedelkov D. Development of multiplex mass spectrometric immunoassay for detection and quantification of apolipoproteins C-I, C-II, C-III and their proteoforms. Methods 81, 86–92 (2015).
  Medline CASGoogle Scholar
• 25 Niederkofler EE, Kiernan UA, O'Rear J et al. Detection of endogenous B-type natriuretic peptide at very low concentrations in patients with heart failure. Circ. Heart Fail. 1(4), 258–264 (2008).
  Medline CASGoogle Scholar
• 26 Lopez MF, Rezai T, Sarracino DA et al. Selected reaction monitoring-mass spectrometric immunoassay responsive to parathyroid hormone and related variants. Clin. Chem. 56(2), 281–290 (2010).
  Medline CASGoogle Scholar
• 27 Blanpain C, Doranz BJ, Vakili J et al. Multiple charged and aromatic residues in CCR5 amino-terminal domain are involved in high affinity binding of both chemokines and HIV-1 Env protein. J. Biol. Chem. 274(49), 34719–34727 (1999).
  Medline CASGoogle Scholar
• 28 Brandt SM, Mariani R, Holland AU, Hope TJ, Landau NR. Association of chemokine-mediated block to HIV entry with coreceptor internalization. J. Biol. Chem. 277(19), 17291–17299 (2002).
  Medline CASGoogle Scholar
• 29 Lit LC, Wong CK, Tam LS, Li EK, Lam CW. Raised plasma concentration and ex vivo production of inflammatory chemokines in patients with systemic lupus erythematosus. Ann. Rheum. Dis. 65(2), 209–215 (2006).
  Medline CASGoogle Scholar
• 30 Ghanim H, Korzeniewski K, Sia CL et al. Suppressive effect of insulin infusion on chemokines and chemokine receptors. Diabetes Care 33(5), 1103–1108 (2010).
  Medline CASGoogle Scholar
• 31 Matter CM, Handschin C. RANTES (regulated on activation, normal T cell expressed and secreted), inflammation, obesity, and the metabolic syndrome. Circulation 115(8), 946–948 (2007).
  MedlineGoogle Scholar
• 32 Winnik S, Klingenberg R, Matter CM. Plasma RANTES: a molecular fingerprint of the unstable carotid plaque? Eur. Heart J. 32(4), 393–395 (2011).
  Medline CASGoogle Scholar
• 33 von Hundelshausen P, Weber C. Platelets as immune cells: bridging inflammation and cardiovascular disease. Circ. Res. 100(1), 27–40 (2007).
  Medline CASGoogle Scholar
• 34 Koenen RR, Weber C. Platelet-derived chemokines in vascular remodeling and atherosclerosis. Semin. Thromb. Hemost. 36(2), 163–169 (2010).
  Medline CASGoogle Scholar
• 35 Weber C. Chemokines in atherosclerosis, thrombosis, and vascular biology. Arterioscler. Thromb. Vasc. Biol. 28(11), 1896 (2008).
  Medline CASGoogle Scholar
• 36 Oran PE, Sherma ND, Borges CR, Jarvis JW, Nelson RW. Intrapersonal and populational heterogeneity of the chemokine RANTES. Clin. Chem. 56(9), 1432–1441 (2010).
  Medline CASGoogle Scholar
• 37 Lim JK, Burns JM, Lu W, DeVico AL. Multiple pathways of amino terminal processing produce two truncated variants of RANTES/CCL5. J. Leukoc. Biol. 78(2), 442–452 (2005).
  Medline CASGoogle Scholar
• 38 Lim JK, Lu W, Hartley O, DeVico AL. N-terminal proteolytic processing by cathepsin G converts RANTES/CCL5 and related analogs into a truncated 4–68 variant. J. Leukoc. Biol. 80(6), 1395–1404 (2006).
  Medline CASGoogle Scholar
• 39 Trenchevska O, Sherma ND, Oran PE, Reaven PD, Nelson RW, Nedelkov D. Quantitative mass spectrometric immunoassay for the chemokine RANTES and its variants. J. Proteomics 116, 15–23 (2015).
  Medline CASGoogle Scholar
• 40 Biancotto A, Wank A, Perl S et al. Baseline levels and temporal stability of 27 multiplexed serum cytokine concentrations in healthy subjects. PLoS ONE 8(12), e76091 (2013).
  MedlineGoogle Scholar
• 41 Herder C, Haastert B, Müller-Scholze S et al. Association of systemic chemokine concentrations with impaired glucose tolerance and Type 2 diabetes: results from the Cooperative Health Research in the Region of Augsburg Survey S4 (KORA S4). Diabetes 54(Suppl. 2), S11–S17 (2005).
  Medline CASGoogle Scholar
• 42 Kotnik P, Fischer-Posovszky P, Wabitsch M. RBP4: a controversial adipokine. Eur. J. Endocrinol. 165(5), 703–711 (2011).
  Medline CASGoogle Scholar
• 43 Ziegelmeier M, Bachmann A, Seeger J et al. Serum levels of adipokine retinol-binding protein-4 in relation to renal function. Diabetes Care 30(10), 2588–2592 (2007).
  Medline CASGoogle Scholar
• 44 Masaki T, Anan F, Tsubone T et al. Retinol binding protein 4 concentrations are influenced by renal function in patients with Type 2 diabetes mellitus. Metabolism 57(10), 1340–1344 (2008).
  Medline CASGoogle Scholar
• 45 Yang Q, Graham TE, Mody N et al. Serum retinol binding protein 4 contributes to insulin resistance in obesity and Type 2 diabetes. Nature 436(7049), 356–362 (2005).
  Medline CASGoogle Scholar
• 46 Cabré A, Lázaro I, Girona J et al. Retinol-binding protein 4 as a plasma biomarker of renal dysfunction and cardiovascular disease in Type 2 diabetes. J. Intern. Med. 262(4), 496–503 (2007).
  Medline CASGoogle Scholar
• 47 Chavarria N, Kato TS, Khan R et al. Increased levels of retinol binding protein 4 in patients with advanced heart failure correct after hemodynamic improvement through ventricular assist device placement. Circ. J. 76(9), 2148–2152 (2012).
  Medline CASGoogle Scholar
• 48 Jaconi S, Rose K, Hughes GJ, Saurat JH, Siegenthaler G. Characterization of two post-translationally processed forms of human serum retinol-binding protein: altered ratios in chronic renal failure. J. Lipid Res. 36(6), 1247–1253 (1995).
  Medline CASGoogle Scholar
• 49 Kiernan UA, Tubbs KA, Nedelkov D, Niederkofler EE, Nelson RW. Comparative phenotypic analyses of human plasma and urinary retinol binding protein using mass spectrometric immunoassay. Biochem. Biophys. Res. Commun. 297(2), 401–405 (2002).
  Medline CASGoogle Scholar
• 50 Nedelkov D, Kiernan UA, Niederkofler EE, Tubbs KA, Nelson RW. Investigating diversity in human plasma proteins. Proc. Natl Acad. Sci. USA 102(31), 10852–10857 (2005).
  Medline CASGoogle Scholar
• 51 Nedelkov D, Phillips DA, Tubbs KA, Nelson RW. Investigation of human protein variants and their frequency in the general population. Mol. Cell Proteomics 6(7), 1183–1187 (2007).
  Medline CASGoogle Scholar
• 52 Trenchevska O, Phillips DA, Nelson RW, Nedelkov D. Delineation of concentration ranges and longitudinal changes of human plasma protein variants. PLoS ONE 9(6), e100713 (2014).
  MedlineGoogle Scholar
• 53 Yang Q, Eskurza I, Kiernan UA et al. Quantitative measurement of full-length and C-terminal proteolyzed RBP4 in serum of normal and insulin-resistant humans using a novel mass spectrometry immunoassay. Endocrinology 153(3), 1519–1527 (2012).
  Medline CASGoogle Scholar
• 54 Sun Q, Kiernan UA, Shi L et al. Plasma retinol-binding protein 4 (RBP4) levels and risk of coronary heart disease: a prospective analysis among women in the nurses’ health study. Circulation 127(19), 1938–1947 (2013).
  Medline CASGoogle Scholar
• 55 Naylor HM, Newcomer ME. The structure of human retinol-binding protein (RBP) with its carrier protein transthyretin reveals an interaction with the carboxy terminus of RBP. Biochemistry 38(9), 2647–2653 (1999).
  Medline CASGoogle Scholar
• 56 Jong MC, Hofker MH, Havekes LM. Role of ApoCs in lipoprotein metabolism: functional differences between ApoC1, ApoC2, and ApoC3. Arterioscler. Thromb. Vasc. Biol. 19(3), 472–484 (1999).
  Medline CASGoogle Scholar
• 57 Hegele RA, Connelly PW, Hanley AJG, Sun F, Harris SB, Zinman B. Common genomic variation in the APOC3 promoter associated with variation in plasma lipoproteins. Arterioscler. Thromb. Vasc. Biol. 17(11), 2753–2758 (1997).
  Medline CASGoogle Scholar
• 58 Jørgensen AB, Frikke-Schmidt R, Nordestgaard BG, Tybjærg-Hansen A. Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. N. Engl. J. Med. 371(1), 32–41 (2014).
  MedlineGoogle Scholar
• 59 Crosby J, Peloso GM, Auer PL et al. Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N. Engl. J. Med. 371(1), 22–31 (2014).
  MedlineGoogle Scholar
• 60 Huff MW, Hegele RA. Apolipoprotein C-III: going back to the future for a lipid drug target. Circ. Res. 112(11), 1405–1408 (2013).
  Medline CASGoogle Scholar
• 61 Graham MJ, Lee RG, Bell TA et al. Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans. Circ. Res. 112(11), 1479–1490 (2013).
  Medline CASGoogle Scholar
• 62 Bondarenko PV, Cockrill SL, Watkins LK, Cruzado ID, Macfarlane RD. Mass spectral study of polymorphism of the apolipoproteins of very low density lipoprotein. J. Lipid Res. 40(3), 543–555 (1999).
  Medline CASGoogle Scholar
• 63 Nicolardi S, van der Burgt YE, Wuhrer M, Deelder AM. Mapping O-glycosylation of apolipoprotein C-III in MALDI-FT-ICR protein profiles. Proteomics 13(6), 992–1001 (2013).
  Medline CASGoogle Scholar
• 64 Wada Y, Kadoya M, Okamoto N. Mass spectrometry of apolipoprotein C-III, a simple analytical method for mucin-type O-glycosylation and its application to an autosomal recessive cutis laxa type-2 (ARCL2) patient. Glycobiology 22(8), 1140–1144 (2012).
  Medline CASGoogle Scholar
• 65 Jian W, Edom RW, Wang D, Weng N, Zhang SW. Relative quantitation of glycoisoforms of intact apolipoprotein C3 in human plasma by liquid chromatography-high-resolution mass spectrometry. Anal. Chem. 85(5), 2867–2874 (2013).
  Medline CASGoogle Scholar
• 66 Balog CI, Mayboroda OA, Wuhrer M, Hokke CH, Deelder AM, Hensbergen PJ. Mass spectrometric identification of aberrantly glycosylated human apolipoprotein C-III peptides in urine from Schistosoma mansoni-infected individuals. Mol. Cell Proteomics 9(4), 667–681 (2010).
  Medline CASGoogle Scholar
• 67 Nicolardi S, van der Burgt YE, Dragan I, Hensbergen PJ, Deelder AM. Identification of new apolipoprotein-CIII glycoforms with ultrahigh resolution MALDI-FTICR mass spectrometry of human sera. J. Proteome Res. 12(5), 2260–2268 (2013).
  Medline CASGoogle Scholar
• 68 Yassine HN, Trenchevska O, Ramrakhiani A et al. The association of human apolipoprotein C-III sialylation proteoforms with plasma triglycerides. PLoS ONE 10(12), e0144138 (2015).
  MedlineGoogle Scholar
• 69 Koska J, Yassine H, Trenchevska O et al. Disialylated apolipoprotein C-III proteoform is associated with improved lipids in prediabetes and Type 2 diabetes. J. Lipid Res. 57(5), 894–905 (2016).
  Medline CASGoogle Scholar
• 70 O'Brien KD, Chait A. Serum amyloid A: the ‘other’ inflammatory protein. Curr. Atheroscler. Rep. 8(1), 62–68 (2006).
  MedlineGoogle Scholar
• 71 Uhlar CM, Whitehead AS. Serum amyloid A, the major vertebrate acute-phase reactant. Eur. J. Biochem. 265(2), 501–523 (1999).
  Medline CASGoogle Scholar
• 72 Sellar GC, Oghene K, Boyle S, Bickmore WA, Whitehead AS. Organization of the region encompassing the human serum amyloid A (SAA) gene family on chromosome 11p15.1. Genomics 23(2), 492–495 (1994).
  Medline CASGoogle Scholar
• 73 Sipe J. Revised nomenclature for serum amyloid A (SAA). Nomenclature Committee of the International Society of Amyloidosis. Part 2. Amyloid 6(1), 67–70 (1999).
  Medline CASGoogle Scholar
• 74 Ducret A, Bruun CF, Bures EJ, Marhaug G, Husby G, Aebersold R. Characterization of human serum amyloid A protein isoforms separated by two-dimensional electrophoresis by liquid chromatography/electrospray ionization tandem mass spectrometry. Electrophoresis 17(5), 866–876 (1996).
  Medline CASGoogle Scholar
• 75 Tolson J, Bogumil R, Brunst E et al. Serum protein profiling by SELDI mass spectrometry: detection of multiple variants of serum amyloid alpha in renal cancer patients. Lab. Invest. 84(7), 845–856 (2004).
  Medline CASGoogle Scholar
• 76 Loo D, Mollee PN, Renaut P, Hill MM. Proteomics in molecular diagnosis: typing of amyloidosis. J. Biomed. Biotechnol. 754109 (2011).
  MedlineGoogle Scholar
• 77 Kiernan UA, Tubbs KA, Nedelkov D, Niederkofler EE, Nelson RW. Detection of novel truncated forms of human serum amyloid A protein in human plasma. FEBS Lett. 537(1–3), 166–170 (2003).
  Medline CASGoogle Scholar
• 78 Yassine HN, Trenchevska O, He H et al. Serum amyloid a truncations in Type 2 diabetes mellitus. PLoS ONE 10(1), e0115320 (2015).
  MedlineGoogle Scholar
• 79 Egashira M, Takase H, Yamamoto I, Tanaka M, Saito H. Identification of regions responsible for heparin-induced amyloidogenesis of human serum amyloid A using its fragment peptides. Arch. Biochem. Biophys. 511(1–2), 101–106 (2011).
  Medline CASGoogle Scholar
• 80 Lacey JM, Bergen HR, Magera MJ, Naylor S, O'Brien JF. Rapid determination of transferrin isoforms by immunoaffinity liquid chromatography and electrospray mass spectrometry. Clin. Chem. 47(3), 513–518 (2001).
  Medline CASGoogle Scholar
• 81 Lenters-Westra E, Schindhelm RK, Bilo HJ, Slingerland RJ. Haemoglobin A1c: historical overview and current concepts. Diabetes Res. Clin. Pract. 99(2), 75–84 (2013).
  Medline CASGoogle Scholar
• 82 Duncan MW, Nedelkov D, Walsh R, Hattan SJ. Applications of MALDI mass spectrometry in clinical chemistry. Clin. Chem. 62(1), 134–143 (2016).
  Medline CASGoogle Scholar
• 83 Cheng K, Chui H, Domish L, Hernandez D, Wang G. Recent development of mass spectrometry and proteomics applications in identification and typing of bacteria. Proteomics Clin. Appl. 10(4), 346–357 (2016).
  Medline CASGoogle Scholar